TAD Pharma GmbH Sustainability Profile
TAD Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1994, the company has established itself as a trusted provider of high-quality generic medications, focusing on therapeutic areas such as pain management, cardiovascular health, and infectious diseases. TAD Pharma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. With a strong emphasis on research and development, the company has achieved significant milestones, including the successful launch of several key generic drugs that have enhanced patient access to essential treatments. Recognised for its reliability and expertise, TAD Pharma continues to strengthen its market position, contributing to the global healthcare landscape with its unique offerings and dedication to excellence.
DitchCarbon Score
How does TAD Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
TAD Pharma GmbH's score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
TAD Pharma GmbH, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Krka, d. d., which may influence its climate commitments and reporting practices. While TAD Pharma GmbH has not established its own reduction targets or climate pledges, it is important to note that it inherits certain sustainability initiatives from its parent company, Krka, d. d. This includes participation in the Carbon Disclosure Project (CDP), where emissions data and performance metrics are cascaded from Krka, d. d. to TAD Pharma GmbH. However, specific details regarding the emissions figures or reduction targets from Krka, d. d. are not provided in the available data. As a subsidiary, TAD Pharma GmbH may align its climate strategies with those of Krka, d. d., which is known for its commitment to sustainability and reducing environmental impact. The absence of specific emissions data and reduction initiatives at TAD Pharma GmbH highlights the need for further transparency and commitment to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 66,245,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 |
How Carbon Intensive is TAD Pharma GmbH's Industry?
How Carbon Intensive is TAD Pharma GmbH's Location?
TAD Pharma GmbH's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 81% of Scope 3 emissions.
Top Scope 3 Categories
TAD Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
TAD Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
